What's new?
10/07/2018

Paris, France, July 10th. 2018. Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.

ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.

ReCor Medical is an innovative medical device company that developed the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.

Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”

Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”

Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”

Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.

For more information, please contact:
SOFINNOVA PARTNERS
International: Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com
United States: Kate Barrette
Tel: +1 212 223 0561
e-mail: kbarrette@rooneyco.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management. For more information: www.sofinnova.fr

About ReCor Medical, Inc.
ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System’s intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a feasibility study of patients with resistant hypertension) and REQUIRE (a pivotal study of patients with resistant hypertension in Japan and Korea), and launch the RADIANCE II pivotal study (a study of patients with moderate hypertension) in the United States and Europe.
http://www.recormedical.com/

About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd.
Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.
http://www.otsuka.com/en/

Established in 2011, Otsuka Medical Devices Co., Ltd. is a fully-owned subsidiary of Otsuka Holdings and one of its core operating subsidiaries. Otsuka Medical Devices focuses on the development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment.
Otsuka Medical Devices conducts the REQUIRE trial for renal denervation in hypertensive patients (n=140), who are uncontrolled on 3 or more medications including a diuretic, in Japan and Korea through its subsidiary JIMRO Co., Ltd.
http://www.omd.otsuka.com/en/

04/06/2014

Unique Delivery Catheter Replicates
Conventional Stent Implantation Technique

PRINCETON, N.J. and PARIS – June 4, 2014 – STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced the signing of the acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a novel stent delivery system. The acquisition is subject to closing conditions.

The catheter technology will enable the implantation of the Self-Apposing stent in the same manner as a conventional balloon-expandable stent. To release the stent in the vessel at the desired location, the cardiologist inflates a small balloon that splits open the stent-containing sheath. This technology has been used as part of Cappella’s Sideguard® coronary bifurcation stent, which is CE Marked in Europe and has been clinically validated by an extensive number of Sideguard stent implants. Cappella Peel Away Inc. assets consist of a license agreement on patents related to the novel peel away sheath technology for a stent delivery system, technical specifications and drawings, clinical and regulatory documentation and equipment from Cappella Inc. The latter will retain the rights to the peel-away sheath technology for its Sideguard coronary bifurcation stent and for other potential applications including peripheral vascular indications.

STENTYS will incorporate the technology into its next-generation delivery system for the company’s line of bare metal and drug-eluting stents and expects to start commercializing these in 2015. Gonzague Issenmann, co-founder and Chief Executive Officer of STENTYS said: “This is STENTYS’ first strategic acquisition, and it results from our active research efforts, including constant monitoring of the landscape for complementary tools to add to our portfolio. We are very excited about the potential for the Cappella Peel Away catheters to offer cardiologists an even friendlier user experience for implantation of our stents and allow more heart attack patients to benefit from STENTYS’ Self-Apposing technology.”

About the STENTYS Self-Apposing® Stent
The STENTYS Self-Apposing® Stent addresses the stent-sizing dilemma that cardiologists are confronted with when treating heart attack patients or patients with atypical artery anatomy. Its flexible, self expanding design takes the shape of the patient’s unique vessel anatomy and apposes to the irregular contours of a blood vessel, in particular after an AMI as the vessel dilates and the clot dissolves. It reduces the risk of malapposition and complications associated with conventional stents in this setting. The STENTYS Self-Apposing Stent has been marketed in Europe since receiving CE Mark in 2010. The STENTYS Sirolimus-eluting stent should receive the CE Mark during the second half of 2014.

About STENTYS
STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS’ Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low one year mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. More information is available at www.stentys.com.

About CAPPELLA
Cappella Inc. is the parent company of ArraVasc Ltd. (www.arravasc.com), which is involved in developing, manufacturing and marketing novel peripheral balloons and catheters. ArraVasc’s first product line, Pirouette™, is a CE marked, industry leading low profile 4F PTA catheter for below the knee application.

This press release contains forward looking statements about the Company’s business. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company’s products, market acceptance of the Company’s products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, including with respect to a pre-market approval for the Company’s BMS, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 “Risk Factors” of the Company’s 2011 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers on August 27, 2013 under number R.13-040 as such section may be updated from time to time.

STENTYS
Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap.
Financial Communication / Investor Relations
Dusan Oresansky / Pierre Laurent
Tel.: +33 (0)1 44 71 94 93
stentys@newcap.fr

STENTYS is listed on Comp. B of the NYSE Euronext Paris
ISIN: FR0010949404 – Ticker: STNT
US: MacDougall Biomedical Communications
Charles Liles, Tel.: 781 235 3060
Christine Labaree or Hunter Marshall, Tel.: 650 339 7533
stentys@macbiocom.com

23/05/2014

Final Results from APPOSITION IV Study Presented at EuroPCR:

  •  No late loss and perfect strut coverage at 9-months
  •  Faster arterial healing compared to conventional drug-eluting stents

PRINCETON, N.J. and PARIS – May 20, 2014 – STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today presented final results from the APPOSITION IV study of its new Self-Apposing sirolimus-eluting stent (SES) during the Hotline session at the EuroPCR conference in Paris.

APPOSITION IV enrolled 152 patients experiencing ST-elevation myocardial infarction (STEMI) and was the first clinical trial to evaluate the novel Self-Apposing sirolimus-eluting stent, which was compared to Medtronic’s Resolute® zotarolimus-eluting stent at two different time points, 4 and 9 months. The evaluation was based on two imaging modalities: Quantitative Coronary Angiography (QCA) to measure the difference in artery diameters between implantation and follow-up, and Optical Coherence Tomography (OCT) to quantify the number of stent struts apposed and “covered” by tissue, an indication that the endothelial cells lining the artery wall have grown around the stent and that the vessel has healed.

At 9 months, the STENTYS SES showed no reduction in artery lumen diameter (Late Lumen Loss of 0.04mm ± 0.43 under QCA) with a near perfect arterial healing (99% covered struts at 9 months under OCT), demonstrating stent efficacy and safety.

Stent apposition was statistically better in the STENTYS group than the balloon-expandable group at 4 months (0.07% malapposed struts vs 1.16%, p=0.005), and a greater percentage of STENTYS stents were fully covered (33% vs 4%, p=0.02). At 9 months, strut apposition and coverage were similar in both groups. The results confirm that arteries with STENTYS SES healed faster than with balloon-expandable drug-eluting stents.
« In the APPOSITION IV trial, we found that the addition of sirolimus elution to the STENTYS platform brings the best of both worlds together for heart attack patients,” said Robert-Jan van Geuns, M.D., Ph.D., Erasmus Medical Center (Rotterdam, the Netherlands), co-Principal investigator. ”An efficacious drug with a perfectly apposed stent over time ensures fast healing and an open vessel in the long run. »

« We are thrilled with the results and very grateful to the APPOSITION IV study investigators for further advancing the knowledge and clinical experience of the Self-Apposing technology, » said Gonzague Issenmann, CEO and co-founder of STENTYS. « With these study results, our sirolimus-eluting stent could receive CE Mark as soon as the second half of this year. »

About the STENTYS Self-Apposing® Stent
The STENTYS Self-Apposing® Stent addresses the stent-sizing dilemma that cardiologists are confronted with when treating heart attack patients or patients with atypical artery anatomy. Its flexible, self expanding design takes the shape of the patient’s unique vessel anatomy and apposes to the irregular contours of a blood vessel, in particular after an AMI as the vessel dilates and the clot dissolves. It reduces the risk of malapposition and complications associated with conventional stents in this setting. The STENTYS Self-Apposing Stent has been marketed in Europe since receiving CE Mark in 2010. The STENTYS Sirolimus-eluting stent should receive the CE Mark during the second half of 2014.

About the APPOSITION IV Study
APPOSITION IV is a prospective, randomized, four-arm, multi-center study designed to compare the STENTYS Sirolimus eluting stent (90 patients) with Medtronic Resolute® (62 patients) in the treatment of ST-elevation Myocardial Infarction. Patients were followed up at either 4 months (63 patients) or 9 months (89 patients). The endpoints are strut apposition and coverage under OCT at 4 and 9 months.

About STENTYS
STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS’ Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low one year mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. More information is available at www.stentys.com.

This press release contains forward looking statements about the Company’s business. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company’s products, market acceptance of the Company’s products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, including with respect to a pre-market approval for the Company’s BMS, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 “Risk Factors” of the Company’s 2011 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers on August 27, 2013 under number R.13-040 as such section may be updated from time to time.

STENTYS
Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap.
Financial Communication / Investor Relations
Dusan Oresansky / Pierre Laurent
Tel.: +33 (0)1 44 71 94 93
stentys@newcap.fr

STENTYS is listed on Comp. B of the NYSE Euronext Paris
ISIN: FR0010949404 – Ticker: STNT
US: MacDougall Biomedical Communications
Charles Liles, Tel.: 781 235 3060
Christine Labaree or Hunter Marshall, Tel.: 650 339 7533
stentys@macbiocom.com

23/05/2014

Amsterdam, the Netherlands – May 20, 2014: Avantium, a leading technology company known for its collaborations with iconic market players such as The Coca-Cola Company and Danone, today was named by Cleantech Group (CTG), as European Cleantech Company of the Decade.

“Making PEF the next generation plastic is our goal: a 100% biobased plastic with enhanced performance over existing packaging materials at competitive costs. It is a long and challenging road to the top, but we are enjoying it and we are certain that we will get there. It is an honour to be selected by the Cleantech Group as European Cleantech Company of the decade. It makes us realize again how unique and immense the development and commercialization of PEF is. We have created a strong market pull through our partnerships with The Coca-Cola Company, Danone and ALPLA for the development of PEF bottles forwater, soft drinks, food and personal care. This year our focus will be on commercializing PEF: by the engineering & design of our first commercial plant,” said Tom van Aken, CEO of Avantium.

This one-off award was made in connection with the 10th anniversary Cleantech ForumEurope, held in Stockholm this year. The award was made in Stockholm’s City Hall, the venue of the annual Nobel Prize ceremony.

“To identify the best five European cleantech companies of the decade would be an impossible task. After all, how can you meaningfully compare, say, a profitable ESCO with a pre-revenue bio-materials developer?” said Sheeraz Haji, CEO, CTG. “Instead, we set out to select private companies that got started and have achieved impressive results in the timeframe since we first conceived of a Cleantech Forum Europe. We sought companies whose stories are illustrative of the collective journey we have all been on, and whose promise for 2014 and beyond is exciting and speaks to the sustainable innovation opportunities in front of us.”

“Avantium was picked because it has been the only European company to have been in the top 10 European companies within the Global Cleantech 100 for the past four years,” explained Richard Youngman, Managing Director Europe & Asia, CTG. “It represents the exciting promise of renewable chemicals, as well as the challenge of building capitalintensive companies.”

About Avantium
Avantium is a leading technology company specialized in the area of advanced highthroughput R&D. The company develops and commercializes YXY – the brand name for its cost competitive technology platform to catalytically convert plant based materials into biobased chemicals and bioplastics like PEF. PEF is a novel 100% biobased polyester withenhanced barrier, thermal and mechanical properties over existing packaging materials. These properties enable new packaging innovations to make lighter, thinner, smaller andstronger bottles, to extend product shelf life and to provide supply chain benefits. Combined with the significant reduction in carbon footprint, PEF fulfils key criteria to become the next generation biobased plastic for bottles, film and fibers. Together with The Coca-Cola Company, Danone and ALPLA Avantium works on the commercialization of the next generation plastic. Avantium’s business unit Catalysis offers solutions ranging from sophisticated R&D systems and services to fully integrated long-tercollaborative partnerships. Avantium’s headquarters are based in Amsterdam, the Netherlands, and Avantium is running an YXY pilot plant in Geleen, the Netherlands. Details atwww.avantium.com.

About Cleantech Group (CTG)
CTG helps clients accelerate sustainable innovation. The company’s i3 market intelligence platform, which tracks over $7 billion of deal flow annually across 23,000+ cleantech companies, allows subscribers to find, vet, and connect with entrepreneurs—efficiently building an innovation pipeline. Cleantech Forums bring the i3 platform to life by convening thought leaders and innovators around diverse themes in innovation. CTG’s Advisory Services leverage expertise in designing and executing corporate strategies for sustainable growth and innovation sourcing. Details at www.cleantech.com.

MEDIA CONTACTS:
Dominique Levant
Avantium
Tel.: +31 (0)20 586 01 32
Email: marketing@avantium.com
Millen Paschich
Cleantech Group
Tel: +1 (415) 233-9712
Email: media-services@cleantech.com

21/05/2014

Lysogène développe une thérapie contre le syndrome de Sanfilippo de Type A, une maladie neurodégénérative chez l’enfant actuellement sans traitement.

Paris, 21 mai 2014 – Lysogène, spécialisée dans la thérapie génique ciblant les maladies neurologiques orphelines, a levé 16,5 M€ lors de d’un tour de table de série A. Le financement a été mené par Sofinnova Partners, qui après avoir soutenu la société en phase d’amorçage de ce tour de table, renforce sa participation et devient le premier actionnaire institutionnel. Le financement a été co-mené avec de nouveaux investisseurs, Bpifrance, via le fonds Innobio, et Novo Seeds. Rafaèle Tordjman, Chahra Louafi et Henrijette Richter, respectivement de Sofinnova Partners, Bpifrance/Innobio et Novo Seeds (Novo A/S), rejoignent le Conseil d’administration Lysogène.
Lysogène a été créée en 2009 par Karen Aiach, PDG, et le Professeur Olivier Danos, PhD, Conseiller scientifique, qui bénéficie d’une reconnaissance internationale dans le domaine de la thérapie génique et qui, entre autres fonctions, a été le Directeur scientifique de Genethon et le Directeur du consortium de thérapie génique à l’UCL (University College of London). Lysogène est spécialisée dans la thérapie génique intracérébrale pour le traitement de maladies neurodégénératives, telles que le syndrome de Sanfilippo de Type A, une maladie rare extrêmement sévère, mortelle dans l’enfance, qui touche près d’une naissance sur 100 000. Le syndrome de Sanfilippo est une Maladie de Surcharge Lysosomale (MSL) pour laquelle il n’y a actuellement aucun traitement. En 2013, la société a finalisé avec succès une étude phase I-II sur des patients atteints du syndrome de Sanfilippo.
La technologie de Lysogène vise à apporter directement dans le cerveau du jeune patient une version fonctionnelle du gène déficient à l’origine de la maladie. Unique et révolutionnaire, cette approche permet de cibler le système nerveux central et d’y produire l’enzyme déficitaire. Les bénéfices sont multiples : reposant sur une administration unique, et non répétée, ce traitement est moins contraignant pour les patients et leurs familles. Par ailleurs, agissant directement sur la cause, il permet d’envisager de soigner la maladie, et non uniquement de mieux gérer les symptômes. Grâce aux fonds levés, Lysogène va accélérer le développement clinique de son produit phare ciblant les patients souffrants du syndrome de Sanfilippo de Type A, en vue d’une autorisation réglementaire de mise sur le marché en Europe et aux Etats-Unis. Le financement permettra également l’entrée en clinique d’un deuxième produit de thérapie génique intracérébrale.
Karen Aiach, PDG de Lysogène, ajoute : « Le soutien continu de Sofinnova Partners depuis plusieurs mois a constitué une chance pour Lysogène. Leur présence en phase d’amorçage de ce prestigieux tour de table nous a permis de franchir de nouvelles étapes décisives. La société a également été capable d’attirer des investisseurs de premier plan comme Bpifrance/Innobio et Novo Seeds. Aujourd’hui, Lysogène prépare la phase clinique pivot de son premier produit et prévoit de développer rapidement un deuxième produit, toujours dans le domaine des maladies génétiques affectant le système nerveux central pour lesquelles les besoins des patients et des familles sont encore largement insatisfaits ».
Rafaèle Tordjman, MD, PhD, Partenaire Associé chez Sofinnova Partners, déclare : « Nous sommes heureux d’accompagner une équipe aussi dynamique. Les développements réalisés en moins de cinq ans sont extraordinaires et nous sommes convaincus que la plateforme technologique de Lysogène apportera une solution thérapeutique, aujourd’hui inexistante, à des patients particulièrement vulnérables ».
Chahra Louafi, Directrice d’Investissements chez Bpifrance/Innobio indique: « Nous sommes ravis de soutenir Lysogène dans ses développements. L’approche par thérapie génique développée par Lysogène pour le traitement du syndrome de Sanfilippo de Type A est la plus avancée, et les premiers résultats cliniques obtenus sont très encourageants ».

CONTACTS PRESSE SOFINNOVA PARTNERS Bpifrance
STRATEGIES & IMAGE Nathalie Police
Anne REIN nathalie.police@bpifrance.fr
anne.rein@strategiesimage.com + 33 1 41 79 95 26
+33 6 03 35 92 05

À propos du Syndrome de Sanfilippo de Type A
Le syndrome Sanfilippo de Type A (Mucopolysaccharidose III de Type A ou MPSIIIA) est une Maladie de Surcharge Lysosomale (MSL) rare et mortelle due à un déficit enzymatique en N-sulfoglucosamine sulfohydrolase (SGSH). Le principal symptôme clinique est une neurodégénérescence condamnant les enfants atteints à une espérance de vie comprise entre 10 et 20 ans. Les MSLs sont un groupe de plus de 50 maladies héréditaires généralement caractérisées par un déficit en une ou plusieurs enzymes Les Maladies de Surcharge Lysosomale (MSL) sont un groupe de plus de 50 maladies héréditaires généralement caractérisées par un déficit en une ou plusieurs enzymes qui dégradent les glycanes, les chaînes glucidiques des glycoprotéines, des protéoglycanes et des glycolipides. Les MSLs sont la cause la plus fréquente de la maladie neurodégénérative pédiatrique, leur incidence combinée totale est supérieure à 1 pour 8.000 naissances.

À propos de Lysogène
Créée en 2009 par Karen Aiach, LYSOGENE est la seule société de biotechnologie au monde spécialisée dans le développement de thérapies géniques intracérébrales visant à traiter les maladies à atteinte du système nerveux central, comme les maladies lysosomales, première cause de mortalité neurodégénérative chez l’enfant.
Pour en savoir plus, consultez www.lysogene.com

À propos de Sofinnova Partners
Sofinnova Partners est une société de capital-risque indépendante basée à Paris. Depuis plus de 40 ans, la société a financé près de 500 sociétés – start-up, spin-off et opérations de retournement. Elle a accompagné les plus grands entrepreneurs européens dans le domaine des sciences de la vie. Avec 1,3 milliard d’euros sous gestion, l’équipe de Sofinnova Partners, reconnue pour sa capacité à aider et à soutenir les entreprises de son portefeuille de la création à la sortie, a permis l’émergence de leaders sur leurs marchés.
Pour en savoir plus, consultez sofinnova.social-unit.fr

À propos de Bpifrance
Créée par la loi du 31 décembre 2012, Bpifrance (banque publique d’investissement) est issu du rapprochement d’OSEO, du FSI, de CDC Entreprises et de FSI Régions. Ses deux actionnaires sont l’État et la Caisse des Dépôts. Il a pour vocation d’accompagner les entreprises (PME, ETI et entités de taille plus importante à dimension stratégique pour l’économie française), de l’amorçage jusqu’à la cotation en bourse, en crédit, en garantie et en fonds propres. Bpifrance assure en outre des services d’accompagnement et de soutien renforcé à l’innovation, à l’export et à la croissance externe. Il représente un interlocuteur unique des entrepreneurs dans chaque région pour tous leurs besoins en financement et en investissement.
InnoBio est un FCPR, de 139 M€, géré par Bpifrance qui en est également souscripteur (37 %) aux côtés des principaux laboratoires pharmaceutiques mondiaux (Sanofi Aventis, GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda, Boehringer-Ingelheim) opérant sur le territoire national. L’objectif principal du fonds est d’investir au capital de sociétés fournissant des produits et services technologiques et innovant dans le domaine de la santé.
Pour plus d’information : www.bpifrance.fr – suivez nous sur Twitter : @bpifrance

À propos de Novo A/S
Novo A/S, la société mère de Novo Group, gère les actifs de la Novo Nordisk Foundation, valorisée à plus de 30 milliards de dollars. Novo A/S est une société privée détenue à 100 % par la Novo Nordisk Foundation. En plus d’être l’actionnaire majoritaire de Novo Nordisk A/S et de Novozymes A/S, Novo A/S intervient en amorçage et capital-risque auprès d’entreprises en développement et prend des participations significatives dans des entreprises matures dans le domaine des sciences de la vie et des biotechnologies. Elle gère également un vaste portefeuille d’actifs financiers.
Pour plus d’information, consultez : www.novo.dk

01/05/2014

• Contract guarantees sales volume for Sarnia plant during its first three years ofoperation
• Agreement ensures BioAmberis the principal supplier to a key emerging buyer of succinic acid
• PTTMCC selection of BioAmber as supplier validates bio-­‐succinic cost competitiveness and quality

Minneapolis, MN, May 1, 2014. BioAmber Inc. (NYSE: BIOA), an industrial biotechnology company producing sustainable chemicals, today announced it has signed its first take-­‐or-­‐pay contract for succinic acid. Under the terms of the agreement, BioAmber will be the principal supplier of bio-­‐ succinic acid to PTTMCC Biochem for the production of a biodegradable plastic in Thailand. PTTMCC Biochem Company Limited (PTTMCC) is a joint venture established by Mitsubishi Chemical Corporation, Japan’s leading chemical company and PTT Public Company Limited, Thailand’s largest oil and gas company. The joint venture will produce and sell polybutylene succinate (PBS), a biodegradable plastic made from succinic acid and 1,4 butanediol (BDO).
PTTMCC is constructing a PBS plant in Rayong, Thailand that will have anannual production capacity of
20,000 tons. The PBS plant is expected to be operational in the first half of 2015 and will consume approximately 14,000 tons of succinic acid per year at full capacity.

BioAmber plans to supply PTTMCC from its 30,000 ton per year plant under construction in Sarnia, Canada. After the commissioning and start up periods for both plants in 2015, BioAmber will exclusively supply a minimum of 80% of PTTMCC’s total bio-­‐succinic acid needs until the end of 2017. The take-­‐or-­‐pay volumes committed by PTTMCC over the three-­‐year term represent approximately half of the total annual quantity of bio-­‐succinic acid that PTTMCC plans to purchase from BioAmber.

“This first succinic acid take-­‐or-­‐pay agreement is an important milestone for BioAmber,” said Babette Pettersen, BioAmber’s Chief Commercial Officer. “This contract guarantees significant sales volume for our Sarnia plant during its first three years of operation. PTTMCC is a major new buyer of bio-­‐ succinic acid and locking up this substantial volume commitment will strengthen our market leadership,” she added.

About BioAmber Inc.
BioAmber (NYSE: BIOA) is an industrial biotechnology company producing sustainable chemicals. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into sustainable chemicals for use in a wide variety of everyday products including plastics, resins, food additives and personal care products.

For more information visit www.bio-­‐amber.com

About PTTMCC Biochem Limited 
PTTMCC Biochem was established to develop and produce Polybutylene Succinate (PBS), a biodegradable plastic that s derived from sugar with a lower carbon footprint than conventional plastics. The company is a joint venture between PTT Public Company Limited of Thailand and Mitsubishi Chemical Corporation of Japan, with the shareholding proportion of 50% each. The company has its head office in Bangkok, and a plant is being built in Map Ta Phut,Rayong, Thailand.

BioAmber Investor Contact
Michael Rice LifeSci Advisors,LLC
1350 Avenue of the Americas 28th Floor New York, NY 10019
646-­‐597-­‐6979
mrice@lifesciadvisors.com

 

10/04/2014

Edimbourg (Royaume-Uni), 10 Avril 2014 – NuCana annonce aujourd’hui avoir levé 41,5 millions d’euros (57 M$) lors d’un tour de financement de série B afin de continuer à développer son portefeuille de produits thérapeutiques anti-cancer. Le tour de table a été mené par un nouvel investisseur, le fonds californien Sofinnova Ventures, avec une contribution importante de l’actionnaire majoritaire basé à Paris, Sofinnova Partners. A leurs côtés, participent également les autres investisseurs existants, Morningside Ventures, Alida Capital International et Scottish Investment Bank.
« C’est un financement majeur qui valide clairement la qualité de NuCana et de sa technologie ProTide », déclare Hugh S. Griffith, PDG et co-fondateur de NuCana. Il poursuit : « Avec le soutien de nos investisseurs, existants et nouveaux, et le fantastique potentiel thérapeutique de notre technologie, notre ambition est de transformer radicalement les options auxquelles ont accès les patients atteints de cancer ».
Les fonds levés vont permettre de développer le produit phare de NuCana, Acelarin, dont les résultats se sont révélés exceptionnels chez les patients résistants aux thérapies conventionnelles sur une variété de cancers. Acelarin sera d’abord développé pour les patients atteints de cancers du pancréas, de la bile, du poumon et des ovaires. Ensuite, courant 2014, la société prévoit de lancer des études cliniques sur un deuxième produit issu de la technologie ProTide (NUC-3373), puis en 2015, sur deux autres produits.
NuCana possède les droits mondiaux exclusifs sur la technologie ProTide appliquée au cancer. Cette technologie permet de court-circuiter les principaux mécanismes de résistance associés aux thérapies conventionnelles, rendant ainsi plus actives et plus sûres certaines chimiothérapies.
Rafaèle Tordjman, MD, PhD, Partenaire Associé chez Sofinnova Partners et membre du Conseil d’administration de NuCana, commente : « La société Gilead a déjà démontré l’efficacité de la technologie ProTide dans le traitement contre le virus de l’hépatite C et du VIH ; à son tour NuCana est en train de mettre en lumière des bénéfices similaires pour les patients atteints de cancers avancés ». Elle poursuit : « Je suis ravie de m’associer de nouveau avec notre partenaire américain, Sofinnova Venture, pour ensemble contribuer à bâtir une entreprise solide sur la base d’une équipe et de travaux scientifiques hors pairs ».
« La plateforme ProTide de NuCana permettra d’apporter aux patients un traitement innovant et supérieur. Menée par une équipe au talent reconnu, nous sommes extrêmement heureux d’accompagner NuCana pour améliorer les traitements et les solutions proposées aux patients atteints de cancer », déclare James Healy, MD, PhD, General Partner chez Sofinnova Ventures. A l’occasion du financement, James Healy et Gerald Chan, co-fondateur et Président de Morningside Ventures, rejoignent le Conseil d’administration de NuCana.

A propos de NuCana
NuCana est société de biopharmacie spécialisée dans le traitement contre le cancer, dont le produit phare est actuellement en phase clinique. Grâce à la nouvelle génération d’agents anti-cancer, la technologie ProTide que développe NuCana a la capacité de contourner les principaux mécanismes de résistance associés aux thérapies couramment utilisées contre le cancer à base d’analogues nucléosidiques, les rendant ainsi plus efficaces et plus sûres pour les patients. Pour plus d’information, merci de visiter : www.nucana.com

A propos de ProTides
La technologie ProTide permet de contourner les principaux mécanismes de résistance et de générer de fortes doses d’agents actifs à l’intérieur des cellules cancéreuses. L’un des aspects fondamentaux de la plateforme ProTide repose sur l’ajout d’un groupe phosphoramidate à un analogue nucléosidique créant ainsi une nouvelle molécule (un ProTide). L’approche ProTide a été inventée par le Pr. Chris McGuigan de l’Université de Cardiff afin de remplacer les traitements couramment utilisés contre le cancer à base d’analogues nucléosidiques (tels que la gemcitabine) par des ProTides plus actifs et sûrs.

A propos de Sofinnova Partners
Sofinnova Partners est une société de capital-risque indépendante basée à Paris, France. Depuis 40 ans, Sofinnova Partners a financé et accompagné près de 500 sociétés à différents stades de leur développement [création, spin-off et opérations de retournement], et accompagne des entrepreneurs européens clefs dans l’industrie des Sciences de la Vie. Sofinnova Partners gère actuellement 1.3 Md€ et se positionne comme investisseur leader en Europe dans l’accompagnement de sociétés jusqu’à la sortie.

A propos de Sofinnova Ventures
Depuis plus de 40 ans, Sofinnova Ventures accompagne les sociétés spécialisées dans la santé pour devenir des leaders sur leur marché. Avec plus de $1,4 Md de capital sous gestion, la société met son capital et son expertise à la disposition des entreprises, de la création jusqu’à la sortie. L’équipe d’investissement, composée de médecins et de chercheurs, bénéficie d’une solide expérience scientifique, opérationnelle et stratégique ; elle est spécialisée dans le financement de produits cliniques en phase avancée et le développement d’entreprises. L’équipe s’associe aux entrepreneurs pour répondre aux besoins médicaux non satisfaits des patients. Sofinnova Ventures dispose de bureaux à Menlo Park et La Jolla en California (Etats Unis), ainsi qu’à Dublin (Irelande). Pour plus d’information, merci de visiter: www.sofinnova.com

Contacts
Pour NuCana
Hugh S. Griffith
info@nucana.com

Pour Sofinnova Partners
Anne Rein
PDG STRATEGIES & IMAGE
+44 131 248 3660 +33 6 03 35 92 05
anne.rein@strategiesimage.com

Pour Sofinnova Ventures
Jennifer James
Partner, Investor Relations and Marketing
+1 650 681 8429
jennifer@sofinnova.com

08/04/2014

Berlin, Germany – 8 April 2014 – NOXXON Pharma announced that data from a Phase IIa pilot study in anemic cancer patients treated with lexaptepid pegol (NOX-H94) will be presented today at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, CA. Lexaptepid pegol is a Spiegelmer® that binds and neutralizes hepcidin, a peptide hormone that negatively regulates serum iron levels. High hepcidin levels, commonly found in patients with cancer or in dialysis patients, lead to iron restriction, also known as functional iron deficiency: a condition in which iron is blocked inside its cellular stores and is thus unavailable for hemoglobin synthesis. This condition, over time, results in anemia of chronic disease. The objective of this single-arm, open label, multi-center study was to evaluate the efficacy, pharmacokinetics, safety and tolerability of treatment with lexaptepid pegol. Twelve cancer patients with anemia (hemoglobin < 10 g/dL) were treated for four weeks with twice weekly intravenous infusions of lexaptepid pegol. This treatment period was followed by a one month observation period. No treatment with ESAs (erythropoiesis stimulating agents) such as EPO (erythropoietin) or iron products was allowed during the study period. The results showed significant increases in hemoglobin levels (>1 g/dL) in 5 of 12 (42%) patients in response to lexaptepid pegol monotherapy. Increased hemoglobin was maintained throughout the follow-up period. For reference, the combination of EPO and intravenous iron in a similar population resulted in a response in 65% of patientsi. Lexaptepid pegol responders showed increases of both red cell and reticulocyte hemoglobin and a decrease in soluble transferrin receptor levels. This latter marker is an indicator of increased iron demand, and was identified as one of two promising diagnostic predictors along with reticulocyte hemoglobin content. Following this positive pilot study, NOXXON plans to initiate soon a new study with lexaptepid pegol in EPO-hypore ponsive dialysis patients.

The title and contributors to the poster presentation at AACR are as follows:

Tuesday, Apr 08, 2014, 8:00 AM -12:00 PM, Hall A-E, Abstract 3847, Poster 8
The anti-hepcidin Spiegelmer® lexaptepid pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study
Pencho Georgiev, Mihaela Lazaroiu, Luminita Ocroteala, Janet Grudeva-Popova,
Emanuil Gheorghita, Mariana Vasilica, Sanda M Popescu, Andrei Cucuianu,
Luciana Summo, Frank Schwoebel, Kai Riecke, Heinz Ludwig

Members of NOXXON’s drug development team will be at the AACR conference to explain the mode of action and clinical potential of this innovative drug candidate.

About NOXXON Pharma AG
NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers. Spiegelmers are chemically synthesized L-stereoisomer oligonucleotide aptamers, a non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical-stage Spiegelmer® therapeutics:
– Emapticap pegol (NOX-E36), an anti-CCL2/MCP-1 (C-C chemokine ligand 2 / Monocyte Chemoattractant Protein-1) Spiegelmer®, has successfully completed a Phase IIa study in patients with type 2 diabetes with albuminuria, achieving proofof- concept. CCL2 is a pro-inflammatory chemokine involved in the recruitment of immune cells to inflamed tissues.
– Olaptesed pegol (NOX-A12), an anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer®, is currently in Phase IIa studies in two hematological cancers, multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CXCL12 is a chemokine mediator of tumor invasion, metastasis, and resistance to therapy.
– Lexaptepid pegol (NOX-H94), an anti-hepcidin Spiegelmer®, has completed a Phase IIa pilot study in cancer patients with anemia and will soon begin a study in EPO-hyporesponsive dialysis patients. Hepcidin is the key regulator of iron metabolism and responsible for the iron restriction leading to anemia of chronic disease.

The Spiegelmer® platform provides the company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well-financed mature biotech company with a strong syndicate of international investors, and approximately 60 employees.

For more information, please visit: www.noxxon.com
Contact:
NOXXON Pharma AG Instinctif Partners
Emmanuelle Delabre
T: +49-30-726247-0
edelabre@noxxon.com
Robert Mayer / Cora Kaiser
T: +49-89-30905189-13
noxxon@instinctif.com
i Ludwig H, et al. European Journal of Cancer, Vol. 45(9), 1603-1615, 2009.

07/04/2014

Bagneux, France, le 7 Avril 2014 – DBV Technologies (Euronext : DBV – ISIN: FR0010417345), créateur de Viaskin®, nouvelle référence dans le traitement de l’allergie, a annoncé aujourd’hui la création d’une filiale américaine, DBV Technologies Inc. ainsi que la nomination de Mlle Susanna Mesa en tant que Vice-Présidente Finance US, Relations Investisseurs & Stratégie.

Les activités cliniques de DBV sont en partie tournées vers les Etats-Unis. C’est le cas en particulier du développement clinique du premier produit de la Société, Viaskin Peanut, premier traitement de l’allergie à l’arachide, dont les Etats unis sont le principal marché potentiel. La création de DBV Technologies Inc. est un élément important du plan stratégique de DBV.

« L’ouverture d’une filiale aux Etats-Unis représente une étape clef dans notre développement. Au moment où nous préparons l’entrée de Viaskin Peanut en phase III, notre but est de continuer d’augmenter la visibilité de DBV au sein de la communauté médicale et financière, et de renforcer notre engagement auprès de la communauté des allergologues américains » a déclaré Pierre-Henri Benhamou, président Directeur Général de DBV Technologies.

Mlle Susanna Mesa, en charge du développement et de la mise en oeuvre de la stratégie Relations Investisseurs aux Etats-Unis est la première employée de DBV Technologies Inc. Mlle Mesa est membre du Comité de Direction et reporte directement à David Schilansky, Directeur Administratif et Financier de DBV.

« Nous sommes très heureux d’accueillir Susanna, qui est extrêmement motivée par la mission de DBV et notre engagement fort auprès de nos actionnaires. Sa connaissance intime des marchés et sa capacité de communication auprès de la communauté financière seront des atouts cruciaux pour continuer d’augmenter notre visibilité aux Etats-Unis. » a déclaré David Schilansky, Directeur Administratif et Financier de DBV Technologies.

Susanna Mesa travaillait précédemment pour le Groupe Trout, une société de conseil en Relations Investisseurs et Stratégie spécialisée dans les sciences de la vie. Chez Trout, Susanna était en charge de l’augmentation de la base d’investisseurs, du pilotage d’opérations de marché et de certaines missions de business développement pour le compte de ses clients. Avant de rejoindre Trout en 2012, Susanna travaillait au développement stratégique de la Leukemia and Lymphoma Society et au sein de l’équipe de vente (equity sales) de Jefferies. Susanna est diplômée de Georgia University (Floride, Etats-Unis).

A propos de DBV Technologies
DBV Technologies ouvre une voie décisive dans le traitement de l’allergie, problème de santé public majeur en constante progression. Les allergies alimentaires représentent un véritable handicap quotidien pour des millions de personnes et un besoin médical hautement insatisfait. La Société, fondée en 2002, a développé une technologie propriétaire unique, brevetée mondialement, permettant d’administrer un allergène par la peau saine sans passage massif dans la circulation sanguine. Ce procédé, appelé Viaskin®, permet ainsi d’associer efficacité et sécurité au cours du traitement qui vise à améliorer la tolérance des patients à l’arachide et à minimiser considérablement les risques de réaction allergique généralisée en cas d’exposition accidentelle à l’allergène. Cette méthode révolutionnaire a fait l’objet d’un important développement ayant conduit à un produit aujourd’hui à un stade industriel. Sa sécurité d’utilisation, cliniquement prouvée, permet d’envisager enfin d’appliquer les techniques de désensibilisation à l’efficacité mondialement reconnue aux formes les plus sévères de l’allergie.

DBV Technologies se focalise sur les allergies alimentaires (lait, arachide) pour lesquelles il n’existe aucun traitement, et a conçu deux produits : Viaskin® Peanut et Viaskin® Milk. Le programme de développement clinique du Viaskin Peanut a obtenu le statut de ‘Fast Track Designation’ de la Food and Drug Administration (‘FDA’). La Société développera par la suite, Viaskin® pour les jeunes enfants allergiques aux acariens – véritable enjeu de santé public – cette pathologie étant l’un des principaux facteurs de risque de l’asthme chez l’enfant.
Les actions DBV Technologies sont négociées sur le compartiment C d’Euronext Paris (mnémonique : DBV, code ISIN : FR0010417345).
Pour plus d’informations sur DBV Technologies, visitez www.dbv-technologies.com

Contacts de DBV Technologies

David Schilansky
Directeur Administratif et Financier
DBV Technologies
Tél. : +33(0)1 55 42 78 75
david.schilansky@dbv-technologies.com

Nathalie Donne
Directeur Business Development & Communications Corporate
Tel. : +33(0)1 55 42 78 72
nathalie.donne@dbv-technologies.com
Contacts de DBV Technologies Relation Investisseur et Média

NewCap.
Communication financière et relations investisseurs
Emmanuel Huynh / Valentine Brouchot
Tél. : +33(0)1 44 71 94 94
dbv@newcap.fr ALIZE RP
Relations Presse
Caroline Carmagnol
Tél. : +33(0)6 64 18 99 59
caroline@alizerp.com

04/04/2014

Anti-CCL2 /MCP-1 Spiegelmer® emapticap pegol (NOX-E36) shows beneficial and lasting effects on albuminuria and glycemic control

Berlin, Germany – 4 April 2014 – NOXXON Pharma AG announced that Phase IIa proof-of-concept data from the emapticap pegol (NOX-E36) trial in diabetic nephropathy were presented at the ISN Nexus Symposium in Bergamo, Italy earlier today.
Emapticap pegol is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in diabetic kidney disease, the most common single cause of chronic kidney failure and end-stage renal disease.
The objective of this randomized, double-blind placebo-controlled multi-center international study was to evaluate the efficacy, pharmacokinetics, safety and tolerability of treatment with emapticap pegol. Seventy-five type 2 diabetic patients with albuminuria on current standard of care to control hypertension, hyperglycemia and dyslipidemia were treated for 12 weeks with twice-weekly subcutaneous emapticap pegol or placebo. This treatment period was followed by a 12 week observational period to study the long-term effect of emapticap treatment on albuminuria. Importantly, the underlying standard of care mandatorily included stable renin-angiotensin system (RAS) blockade, which has been demonstrated to reduce albuminuria and to slow progression of diabetic nephropathy. Emapticap pegol was found to be safe and well tolerated with no treatment-related serious adverse events. For the primary efficacy analysis, patients with major protocol violations, on dual RAS blockade, or with concomitant hematuria and leukocyturia were excluded.
Results showed relevant, statistically significant reductions in urinary albumin excretion and improved glycemic control. Importantly, these effects were independent of hemodynamic changes and maintained after cessation of treatment, suggesting that emapticap pegol interferes with the underlying pathophysiology of diabetic nephropathy. Long-lasting effects on urinary albumin after cessation of treatment are not seen with agents currently approved to treat diabetic nephropathy (ACE inhibitors and ARBsi) or with other agents that act primarily via a hemodynamic mechanism of action such as endothelin A receptor antagonists.
Professor Dr. Hermann Haller, Director of the Department of Nephrology and Hypertension at Hannover Medical School and lead investigator of the study commented: “This Phase IIa study clearly shows that emapticap pegol is exceptionally safe and well tolerated in the target population and produces significant and clinically relevant beneficial effects on albuminuria and glycemic control after only three months of treatment. The observation that these effects are maintained even after cessation of treatment suggests that emapticap pegol interferes with the underlying pathophysiology and may be the first disease-modifying drug for this indication.”
Dr. George Bakris, Professor of Medicine and Director of the ASH Comprehensive Hypertension Center at the University of Chicago Medicine remarked: “From the data I’ve seen, I’m particularly impressed by the dissociation of emapticap pegol’s albuminuria lowering effect from hemodynamics. The fact that this beneficial effect is accompanied by an additional benefit on glycemic control is a unique feature that differentiates this drug from other compounds in development.”

Notes for editors:

About NOXXON Pharma AG
NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers. Spiegelmers are chemically synthesized L-stereoisomer oligonucleotide aptamers, a non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical-stage Spiegelmer® therapeutics:
• Emapticap pegol (NOX-E36), an anti-CCL2/MCP-1 (C-C chemokine ligand 2 / Monocyte Chemoattractant Protein-1) Spiegelmer®, has completed a Phase IIa study in patients with type 2 diabetes with albuminuria. CCL2 is a proinflammatory chemokine involved in the recruitment of immune cells to inflamed tissues.
• Olaptesed pegol (NOX-A12), an anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer®, is currently in Phase IIa studies in two hematological cancers, multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CXCL12 is a chemokine mediator of tumor invasion, metastasis, and resistance to therapy.
• Lexaptepid pegol (NOX-H94), an anti-hepcidin Spiegelmer®, has completed a Phase IIa pilot study in cancer patients with anemia and will soon begin a study in EPO-hyporesponsive dialysis patients. Hepcidin is the key regulator of iron metabolism and responsible for the iron restriction leading to anemia of chronic disease.

The Spiegelmer® platform provides the company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well-financed mature biotech company with a strong syndicate of international investors, and approximately 60 employees.
For more information, please visit: www.noxxon.com
 

Contact:

NOXXON Pharma AG
Instinctif Partners
Emmanuelle Delabre
T: +49-30-726247-0
edelabre@noxxon.com
Robert Mayer / Cora Kaiser
T: +49-89-30905189-13
noxxon@instinctif.com
i ACE – Angiotensin Converting Enzyme, ARB – Angiotensin Receptor Blocker

04/04/2014

Le syndicat d’investisseurs inclue aussi Pfizer Venture Investments et Venrock

Burlingame, CA (Etats Unis). 4 avril 2014 – RefleXion Medical, société d’équipement médical spécialisée dans le traitement du cancer qui développe le premier système de radiothérapie bio-guidée, annonce aujourd’hui avoir levé 8,5 M€ (11.6 M$) lors d’un tour de financement de série A. Le financement a été mené par Sofinnova Partners, rejoint par Pfizer Venture Investments (PVI), et Venrock. A cette occasion, Antoine Papiernik, de Sofinnova Partners, Bill Burkoth de PVI et Colin Cahill de Venrock, rejoignent le Conseil d’administration de la société qui compte déjà Jay Watkins, Président de RefleXion, Dr. Samuel Mazin et Akshay Nanduri, co-fondateurs.

Antoine Papiernik, Partenaire Associé chez Sofinnova Partners, déclare : “Chez Sofinnova Partners nous cherchons à investir auprès d’entrepreneurs visionnaires qui développent des technologies de rupture. RefleXion réunit ces caractéristiques et nous sommes ravis de les accompagner afin de concrétiser leur projet et améliorer radicalement le traitement du cancer”.

La technologie de RefleXion’s combine la tomographie à émission de position (TEP) à la radiothérapie, permettant au signal émis par la tumeur même de guider la délivrance des radiations thérapeutiques. S’appuyant sur un signal biologique comme système de guidage, la technologie de RefleXion devrait permettre en une seule session de diffuser de fortes doses de rayons focalisés sur des lésions cancéreuses multiples tout en épargnant les tissus sains environnants ; un degré de précision actuellement impossible à obtenir avec les traitements aujourd’hui disponibles. Les fonds levés vont permettre de développer les programmes de recherche avec pour objectif de démontrer au plus tôt le potentiel de la technologie de RefleXion sur des patients.

“Avec radiothérapie bio-guidée par la TEP en temps réel, nous avons enfin un moyen de personnaliser le traitement par radiothérapie”, declare Dr. Samuel Mazin, Président de RefleXion et inventeur de la technologie.

Dr. Ralph Weichselbaum, D.K Ludwig Professeur Président du département Radiation et Oncologie à l’Université de Chicago et membre du Conseil Scientifique de RefleXion, poursuit : “Je suis enthousiasmé par le potentiel de la radiothérapie bio-guidée. Parmi les nombreuses applications cliniques, je suis convaincu que le système de RefleXion sera particulièrement adapté pour traiter les cancers oligometastatiques”.

Akshay Nanduri, Vice Président du Business Développement de RefleXion, ajoute “Etre accompagné par un syndicat d’investisseurs spécialisés dans les sciences de la vie de cette qualité va nous permettre de déployer efficacement notre stratégie de croissance et apporter aux patients et aux cliniciens notre système de thérapie innovant ”.

A propos de Sofinnova Partners
Sofinnova Partners est une société de capital-risque indépendante basée à Paris, France. Depuis 40 ans, Sofinnova Partners a financé et accompagné près de 500 sociétés à différents stades de leur développement [création, spin-off et opérations de retournement], et accompagne des entrepreneurs européens clef dans l’industrie des Sciences de la Vie. Sofinnova gère actuellement 1.3 Md€ et se positionne comme investisseur leader en Europe dans l’accompagnement de sociétés jusqu’à la sortie. Pour plus d’informations merci de visiter: sofinnova.social-unit.fr

A propos de RefleXion Medical
RefleXion Medical est une société d’équipement médical spécialisée dans le traitement du cancer. La société développe le premier système de radiothérapie bio-guidée qui a le potentiel de transformer les pratiques de radiothérapie dans le domaine de l’oncologie. La technologie de RefleXion’s combine la tomographie à émission de position (TEP) à la radiothérapie permettant au signal émis par la tumeur même de guider la délivrance des radiations thérapeutiques. Pour plus d’information merci de visiter : www.reflexionmedical.com

Pour plus d’information, merci de contacter :
Akshay NANDURI
akshay[at]reflexionmedical.com

Anne REIN
STRATEGIES & IMAGE
anne.rein@strategiesimage.com
+33 6 03 35 92 05